Orphan nuclear receptor RORγ confers doxorubicin resistance in prostate cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Orphan nuclear receptor RORγ confers doxorubicin resistance in prostate cancer
Authors
Keywords
-
Journal
CELL BIOLOGY INTERNATIONAL
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-06-25
DOI
10.1002/cbin.11411
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype
- (2019) Demin Cai et al. Nature Communications
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Emerging Variants of Castration-Resistant Prostate Cancer
- (2017) Panagiotis J. Vlachostergios et al. Current Oncology Reports
- Tbet or Continued RORγt Expression Is Not Required for Th17-Associated Immunopathology
- (2016) Verena Brucklacher-Waldert et al. JOURNAL OF IMMUNOLOGY
- Benzoxazepines Achieve Potent Suppression of IL-17 Release in Human T-Helper 17 (TH17) Cells through an Induced-Fit Binding Mode to the Nuclear Receptor RORγ
- (2015) Roine I. Olsson et al. ChemMedChem
- Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience
- (2015) R. Petrioli et al. MEDICAL ONCOLOGY
- ROR nuclear receptors: structures, related diseases and drug discovery
- (2014) Yan Zhang et al. ACTA PHARMACOLOGICA SINICA
- Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer
- (2014) C. Geng et al. CANCER RESEARCH
- Nuclear receptors rock around the clock
- (2014) X. Zhao et al. EMBO REPORTS
- REV-ERB and ROR nuclear receptors as drug targets
- (2014) Douglas J. Kojetin et al. NATURE REVIEWS DRUG DISCOVERY
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
- (2012) Oktay Tacar et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
- (2010) Yves Pommier et al. CHEMISTRY & BIOLOGY
- Cancer Statistics, 2009
- (2009) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs
- (2009) Catherine Sánchez et al. PROSTATE
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started